# Nasdaq's Wild Ride: Reverse Splits & Retail Mayhem!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-07-26T14:01:00.334Z
Source: https://newsyai.com/edition/10f7cbfb-7174-4851-b1f3-a26984bb5fbf
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Nasdaq’s Reverse-Split Shitshow: Biotech Burnouts, Singularity Shenanigans & Zeta Zombies – July 26, 2026 Edition!**

Futures still mixed (Dow napping, Nasdaq hopped up on AI/chip juice while crude oil struts like it owns the joint). Yesterday’s FFAI/TRIB/DBGI drama is yesterday’s news. Nasdaq’s reverse-split meat grinder keeps churning out fresh meat for retail degens chasing post-split pops and bears licking their chops over dilution disasters. New rules mean repeat offenders get the delisting boot—no more free cures. Balls-deep into three brand-new volatility addicts where the bull/bear shouting match is louder than a options pit on expiration.

### 1) VYNE Therapeutics Inc. (VYNE): “1-for-50 Biotech Boner vs. Cash-Burn Crematorium & Trial Tombstones”

**Why it’s loud**  
Massive 1-for-50 reverse split effective tomorrow (July 27) for Nasdaq $1 compliance. Skin/therapeutics play hyped as a recovery story. Bulls see any positive trial data or partnership news ripping the shrunken float; bears hammer chronic cash burn, failed execution, and “biotech graveyard” energy.

**Bull case (compliance rocket + trial stiffy)**  
Insane ratio + volume spike + any dermatology or pipeline win = $1–8+ moon. Ride the science fantasy, degens—tiny float turns every rumor into rocket fuel!

**Bear case (dilution gangbang & split limp encore)**  
50x desperation screams endless capital needs, brutal biotech competition, repeated raises = sub-$0.03 cemetery. Short the fade before the next offering tsunami!

**My take, first principles (real science signal vs. listing cancer)**  
Genuine niche in therapeutics offers short-term narrative juice, but massive cash burn, dilution history, stricter Nasdaq rules, and microcap volatility scream unsustainable trap. Real operational moonshot with lottery vibes. Scalp the spunk? **$0.08–2.10** range, **$0.55C** trial pump—**P$0.06** dilution fade.

### 2) Zeta Network Group (ZNB): “1-for-8 Network Narrative vs. Governance Graveyard & Dilution Doldrums”

**Why it’s loud**  
1-for-8 reverse split + par value tweak hitting July 27 amid compliance desperation. Tech/network/media angle hyped as a comeback play. Bulls eye any sector tailwinds or buzz with the tiny post-split float; bears pound weak fundamentals, governance red flags, and “zombie network” vibes.

**Bull case (compliance rocket + tech boner)**  
Big ratio + volume spike + any connectivity or deal news = $1–5+ rip. Ride the narrative fantasy, apes!

**Bear case (dilution gangbang & split limp encore)**  
8x desperation screams ongoing capital hunger, brutal competition, repeated raises = sub-$0.04 graveyard. Short the fade before the next offering tsunami!

**My take, first principles (real tech signal vs. listing cancer)**  
Genuine low-float network appeal offers short-term hype juice, but dilution overhang, stricter Nasdaq scrutiny, and microcap chaos scream trap. Real operational niche with token risk. Scalp it? **$0.09–1.90** range, **$0.48C** network pump—**P$0.07** dilution fade.

### 3) Singularity Future Technology Ltd. (SGLY): “1-for-14 Singularity Dream vs. Logistics Lameness & Dilution Disaster”

**Why it’s loud**  
1-for-14 reverse split effective tomorrow (July 27) for compliance. Future-tech/logistics narrative hyped as a recovery story. Bulls drool over any AI or supply-chain positive with the shrunken float; bears hammer execution flops, weak fundamentals, and “singularity fail” energy.

**Bull case (compliance rocket + tech stiffy)**  
Big ratio + volume spike + any tech or logistics news = $1–6+ rip. Ride the future fantasy, degens!

**Bear case (dilution gangbang & split limp encore)**  
14x desperation screams capital needs, brutal sector competition, repeated raises = sub-$0.03 graveyard. Short the fade before the next offering tsunami!

**My take, first principles (real tech signal vs. listing cancer)**  
Genuine low-float tech/logistics narrative offers short-term hype juice, but dilution history, Nasdaq tightening, and microcap volatility scream unsustainable trap. Real operational moonshot with lottery vibes. Scalp the spunk? **$0.07–1.70** range, **$0.40C** singularity pump—**P$0.05** dilution fade.

**Tape-Side Tactics (VYNE Biotech Blasts, ZNB Network Fails & SGLY Singularity Chaos – July 26 Edition)**  
- **VYNE**: **$0.08–2.10** stiffy; **$0.55C** trial pump, **P$0.06** fade.  
- **ZNB**: **$0.09–1.90** stiffy; **$0.48C** network pump, **P$0.07** fade.  
- **SGLY**: **$0.07–1.70** stiffy; **$0.40C** singularity pump, **P$0.05** fade.  

New split rules still tightening the noose amid crude cock-up and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions!

**Sources** (for tracking every claim above):  
- Reverse splits & reactions: Nasdaq Trader Corporate Actions Alerts, StockTitan, Yahoo Finance calendars (July 26–27, 2026 data).  
- Company announcements & details: PR Newswire, BusinessWire, SEC filings.  
- Nasdaq reverse-split rule changes & compliance: Norton Rose Fulbright analyses, Nasdaq Listing Rules (2025–2026 updates).  
- Broader microcap/premarket context & volatility: Yahoo Finance, recent company filings.
